US OptionsDetailed Quotes

ACRS250516P6000

Watchlist

2.55
0.000.00%

15min DelayClose May 9 16:00 ET

0.00High0.00Low

Aclaris Therapeutics Stock Discussion

Trytosaveabit

May 8 19:22

note the dates

$Aclaris Therapeutics (ACRS.US)$ ATI-2138: Investigational oral covalent ITK/JAK3 inhibitor
● Top Line Results from Phase 2a Trial in AD Expected in June 2025: Dosing is complete in the single arm Phase 2a open-label trial of ATI-2138 designed to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 in patients with moderate-to-severe AD. The Company expects to report top line results in June 2025. Potential target indications under consi...

Growth lover

May 1 02:12

$Aclaris Therapeutics (ACRS.US)$ 13 G FILLED 🚀

This_Guy

Apr 22 19:07

$Aclaris Therapeutics (ACRS.US)$
Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2

Trytosaveabit

Apr 22 19:04

news

$Aclaris Therapeutics (ACRS.US)$ Reuters· 4 mins ago
Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody

$Aclaris Therapeutics (ACRS.US)$

Jaguar8

Dec 4, 2024 06:27

🟢Watchlist Wednesday, December 4. NFA. Check on my previous watchlist. Those without ✅ means they can have delayed market reaction.

Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...